Table 4.
SIR, RR and AER for subsequent primary malignant neoplasms (SPNs) of the salivary glands by different factors among all cancer survivors in the PanCareSurFup cohort.
| SPN of salivary glands | Level | Obs (%) | Exp | SIR (95% CI) | RR (95% CI) | AER (95% CI) | |
|---|---|---|---|---|---|---|---|
| Overall | 64 (100%) | 3.7 | 17.2 (14.4–20.4) | 4.8 (4.0–5.7) | |||
| Sexa | Male | 34 (53%) | 1.8 | 18.5 (13.2–25.9) | 1.0 (1.0–1.0) | 4.8 (3.3–6.8) | |
| Female | 30 (47%) | 1.9 | 15.9 (11.1–22.7) | 0.9 (0.5–1.4) | 4.8 (3.3–7.0) | ||
| pheterogeneity | 0.54 | 0.58 | 0.99 | ||||
| Type of childhood cancera | Leukaemia | 22 (34%) | 0.5 | 40.1 (26.4–60.9) | 4.4 (1.7–11.3) | 8.3 (5.4–12.8) | |
| Leukaemia + RT* | 17 (27%) | 0.3 | 50.5 (36.1–70.7)) | – | – | ||
| Hodgkin lymphoma | 12 (19%) | 0.3 | 35.9 (20.4–63.2) | 4.6 (1.7–12.5) | 12.0 (6.7–21.4) | ||
| Hodgkin lymphoma + RT* | 11 (17%) | 0.2 | 66.2 (43.6–100.5) | – | – | ||
| Non-HL | 5 (8%) | 0.2 | 25.4 (10.6–61.1) | 3.1 (0.9–10.2) | 7.9 (3.2–19.6) | ||
| CNS tumour | 6 (9%) | 0.8 | 7.1 (3.2–15.9) | 1.0 (ref) | 2.0 (0.8–5.0) | ||
| CNS tumour + RT* | 5 (8%) | 0.3 | 16.3 (8.7–30.2) | – | – | ||
| Neuroblastoma | 1 (2%) | 0.1 | 7.8 (1.1–55.0) | 1.0 (0.1–8.5) | 1.4 (0.1–13.4) | ||
| Retinoblastoma | 1 (2%) | 0.2 | 5.1 (0.7–35.9) | 0.8 (0.1–6.7) | 1.1 (0.1–13.1) | ||
| Wilms tumour | 2 (3%) | 0.3 | 7.8 (2.0–31.3) | 1.1 (0.2–5.6) | 1.6 (0.3–7.9) | ||
| Bone sarcoma | 4 (6%) | 0.2 | 18.5 (6.9–49.3) | 2.8 (0.8–9.9) | 6.7 (2.4–18.8) | ||
| Soft tissue sarcoma | 6 (9%) | 0.3 | 20.0 (9.0–44.4) | 2.9 (0.9–9.0) | 6.2 (2.7–14.4) | ||
| Other | 5 (8%) | 0.7 | 7.4 (3.1–17.7) | 1.3 (0.4-4.4) | 2.3 (0.8–6.4) | ||
| pheterogeneity | <0.001 | 0.003 | <0.001 | ||||
| Decade of childhood cancer diagnosisa | <1970 | 15 (23%) | 1.5 | 9.9 (6.0–16.4) | 1.0 (ref) | 4.3 (2.5–7.6) | |
| 1970–1979 | 13 (20%) | 1.0 | 13.3 (7.7–22.9) | 0.7 (0.3–1.5) | 3.4 (1.9–6.1) | ||
| 1980–1989 | 19 (30%) | 0.9 | 22.1 (14.1–34.7) | 0.8 (0.3–1.8) | 4.5 (2.8–7.3) | ||
| 1990–2008 | 17 (27%) | 0.4 | 45.7 (28.4–73.4) | 1.6 (0.5–5.1) | 8.2 (5.1–13.4) | ||
| ptrend | <0.001 | 0.31 | 0.13 | ||||
| Age at childhood cancer (years)a | 0–3 | 14 (22%) | 0.9 | 15.4 (9.1–26.0) | 1.0 (ref) | 3.0 (1.7–5.2) | |
| 4–7 | 14 (22%) | 0.7 | 20.1 (11.9–33.9) | 1.1 (0.5–2.3) | 4.8 (2.8–8.3) | ||
| 8–11 | 16 (25%) | 0.7 | 23.1 (14.2–37.7) | 1.4 (0.6–3.1) | 7.3 (4.4–12.2) | ||
| 12–21 | 20 (31%) | 1.4 | 14.0 (9.0–21.7) | 1.1 (0.5–2.7) | 5.5 (3.4–8.8) | ||
| ptrend | 0.74 | 0.69 | 0.06 | ||||
| Attained age (years)a | <20 | 14 (22%) | 0.4 | 35.3 (20.9–59.6) | 1.0 (ref) | 3.3 (1.9–5.7) | |
| 20–29 | 22 (34%) | 0.9 | 24.7 (16.3–37.5) | 0.7 (0.3–1.5) | 5.0 (3.3–7.8) | ||
| 30–39 | 11 (17%) | 0.9 | 12.1 (6.7–21.9) | 0.4 (0.2–1.0) | 3.9 (2.0–7.3) | ||
| 40–49 | 12 (19%) | 0.8 | 15.3 (8.7–27.0) | 0.6 (0.2–1.6) | 9.3 (5.1–17.0) | ||
| 50+ | 5 (8%) | 0.7 | 6.7 (2.8–16.0) | 0.2 (0.1–0.9) | 8.1 (2.9–22.8) | ||
| ptrend | <0.001 | 0.04 | 0.03 | ||||
| Time since 5-year survival (years)b | 0–9 | 25 (39%) | 0.8 | 32.8 (22.2–48.6) | 1.0 (ref) | 4.3 (2.9–6.4) | |
| 10–19 | 16 (25%) | 0.9 | 17.2 (10.5–28.0) | 0.6 (0.3–1.2) | 4.1 (2.4–6.8) | ||
| 20–29 | 16 (25%) | 0.9 | 17.5 (10.8-28.6) | 0.7 (0.3–1.4) | 7.1 (4.2–11.9) | ||
| 30+ | 7 (11%) | 1.1 | 6.2 (3.0–13.1) | 0.2 (0.1–0.6) | 5.1 (2.1–12.3) | ||
| ptrend | <0.001 | 0.01 | 0.29 | ||||
| Radiotherapy for childhood cancerc,d | Yes | 48 (86%) | 1.4 | 33.5 (25.3–44.5) | 4.9 (1.9–12.7) | 9.9 (7.4–13.2) | |
| No | 5 (9%) | 0.7 | 6.7 (2.8–16.1) | 1.0 (ref) | 1.6 (0.6–4.5) | ||
| Unknown | 3 (5%) | – | – | – | – | ||
| pheterogeneity | <0.001 | <0.001 | <0.001 | ||||
| Chemotherapy for childhood cancerc,d | Yes | 37 (66%) | 1.0 | 36.0 (26.1–49.7) | 1.0 (0.4–2.3) | 8.0 (5.8–11.2) | |
| No | 17 (30%) | 1.1 | 15.6 (9.7–25.1) | 1.0 (ref) | 5.8 (3.5–9.6) | ||
| Unknown | 2 (4%) | – | – | – | – | ||
| pheterogeneity | 0.003 | 0.93 | 0.28 | ||||
Pyrs person-years, Obs observed, Exp expected, SIR standardised incidence ratio, RR relative risk, AER absolute excess risks, HL Hodgkin lymphoma, RT radiotherapy. *Survivors were exposed to radiotherapy.
aRRs were derived from a model including sex, childhood cancer diagnosis, country, decade of childhood diagnosis, age at childhood diagnosis, and attained age.
bRRs were derived from a model including sex, childhood cancer diagnosis, country, decade of childhood diagnosis, age at childhood diagnosis, and follow-up time.
cRRs were derived from a model including sex, country, age at childhood diagnosis, attained age and treatment.
dExcluded Nordic countries (Denmark, Sweden, Norway, Finland, Iceland) and Italy population-based data because of lack of treatment data.